Greg Yothers
Impact in
- Oncology top 0.1%
- Colorectal Cancer Surgical Treatments
- HER2/EGFR in Cancer Research
- Colorectal Cancer Treatments and Studies
- Cancer Treatment and Pharmacology
- Cancer Research top 0.5%
- Breast Cancer Treatment Studies
- Cancer Genomics and Diagnostics
Papers in
- Oncology 54
- Colorectal Cancer Surgical Treatments 21
- Colorectal Cancer Treatments and Studies 18
- Colorectal Cancer Screening and Detection 8
- Cancer Treatment and Pharmacology 5
-
- Genetic factors in colorectal cancer 13
- Co-authors
- Norman Wolmark (41 shared papers)Michael J. O’Connell (28 shared papers)Carmen Joseph Allegra (19 shared papers)Nicholas James Petrelli (11 shared papers)Linda H. Colangelo (11 shared papers)Daniel J. Sargent (24 shared papers)Louis Fehrenbacher (7 shared papers)Soonmyung Paik (11 shared papers)
- Journals
- Journal of Clinical Oncology (40 papers)JNCI Journal of the National Cancer Institute (14 papers)Annals of Oncology (8 papers)Cancer (6 papers)JAMA Oncology (5 papers)
- Partner nations
- United StatesFranceUnited Kingdom
In The Last Decade
Greg Yothers
123 papers receiving 18.6k citations
Greg Yothers's Hit Papers
Peers
Comparison fields: 5 of 136
- Oncology 11.5k
- Cancer Research 3.9k
- Pathology and Forensic Medicine 2.6k
- Pulmonary and Respiratory Medicine 2.4k
- Radiology, Nuclear Medicine and Imaging 1.7k
Countries citing papers authored by Greg Yothers
This map shows the geographic impact of Greg Yothers's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Greg Yothers with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Greg Yothers more than expected).
Fields of papers citing papers by Greg Yothers
This network shows the impact of papers produced by Greg Yothers. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Greg Yothers. The network helps show where Greg Yothers may publish in the future.
Co-authors
The 25 scholars most cited alongside Greg Yothers, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 129 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Trastuzumab plus Adjuvant Chemotherapy for Operable HER2-Positive Breast Cancer Hit paper breakdown → | 2005 | 4380 |
| 2 | Adjuvant Olaparib for Patients with BRCA1 - or BRCA2 -Mutated Breast Cancer Hit paper breakdown → | 2021 | 1164 |
| 3 | Oxaliplatin Combined With Weekly Bolus Fluorouracil and Leucovorin As Surgical Adjuvant Chemotherapy for Stage II and III Colon Cancer: Results From NSABP C-07 Hit paper breakdown → | 2007 | 857 |
| 4 | Preoperative Multimodality Therapy Improves Disease-Free Survival in Patients With Carcinoma of the Rectum: NSABP R-03 Hit paper breakdown → | 2009 | 741 |
| 5 | Assessment of Cardiac Dysfunction in a Randomized Trial Comparing Doxorubicin and Cyclophosphamide Followed by Paclitaxel, With or Without Trastuzumab As Adjuvant Therapy in Node-Positive, Human Epidermal Growth Factor Receptor 2–Overexpressing Breast Cancer: NSABP B-31 Hit paper breakdown → | 2005 | 652 |
| 6 | 2005 | 565 | |
| 7 | 2009 | 533 | |
| 8 | Oxaliplatin As Adjuvant Therapy for Colon Cancer: Updated Results of NSABP C-07 Trial, Including Survival and Subset Analyses Hit paper breakdown → | 2011 | 505 |
| 9 | Phase III Trial Assessing Bevacizumab in Stages II and III Carcinoma of the Colon: Results of NSABP Protocol C-08 Hit paper breakdown → | 2010 | 474 |
| 10 | DNA Mismatch Repair Status and Colon Cancer Recurrence and Survival in Clinical Trials of 5-Fluorouracil-Based Adjuvant Therapy Hit paper breakdown → | 2011 | 453 |
| 11 | Seven-Year Follow-Up Assessment of Cardiac Function in NSABP B-31, a Randomized Trial Comparing Doxorubicin and Cyclophosphamide Followed by Paclitaxel (ACP) With ACP Plus Trastuzumab As Adjuvant Therapy for Patients With Node-Positive, Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer Hit paper breakdown → | 2012 | 432 |
| 12 | 2002 | 423 | |
| 13 | CDX2 as a Prognostic Biomarker in Stage II and Stage III Colon Cancer Hit paper breakdown → | 2016 | 373 |
| 14 | 2014 | 353 | |
| 15 | Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer Hit paper breakdown → | 2022 | 321 |
| 16 | 2010 | 302 | |
| 17 | 2020 | 291 | |
| 18 | 2006 | 289 | |
| 19 | 2012 | 273 | |
| 20 | 2006 | 259 |
About Greg Yothers
Greg Yothers is a scholar working on Oncology, Pathology and Forensic Medicine, Cancer Research, Statistics and Probability and Pulmonary and Respiratory Medicine, having authored 129 papers that have together received 19.3k indexed citations. Recurring topics across this work include Colorectal Cancer Surgical Treatments (21 papers), Colorectal Cancer Treatments and Studies (18 papers), Genetic factors in colorectal cancer (13 papers), Colorectal Cancer Screening and Detection (8 papers), Breast Cancer Treatment Studies (7 papers), Statistical Methods in Clinical Trials (6 papers), Cancer Treatment and Pharmacology (5 papers) and Gastric Cancer Management and Outcomes (4 papers). The work is most often cited by research in Oncology (11.5k citations), Cancer Research (3.9k citations), Pathology and Forensic Medicine (2.6k citations), Pulmonary and Respiratory Medicine (2.4k citations) and Radiology, Nuclear Medicine and Imaging (1.7k citations). Greg Yothers has collaborated with scholars based in United States, France and United Kingdom. Frequent co-authors include Norman Wolmark, Michael J. O’Connell, Carmen Joseph Allegra, Nicholas James Petrelli, Linda H. Colangelo, Daniel J. Sargent, Louis Fehrenbacher, Soonmyung Paik, Richard M. Goldberg and John Bryant. Their work appears in journals such as Journal of Clinical Oncology, JNCI Journal of the National Cancer Institute, Annals of Oncology, Cancer and JAMA Oncology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.